Chapter 13: CISNET Lung Models: Comparison of model assumptions and model structures

Risk Analysis

Volumn 32, Issue SUPPL.1, 2012, Pages

  Mcmahon, Pamela M ^a,b   Hazelton, William D ^c   Kimmel, Marek ^d   Clarke, Lauren D ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c USA   (United States)

^d Rice University   (United States)

^e Cornerstone Systems Northwest ^*  (United States)

Author keywords

Lung cancer; Modeling; Population trends; Tobacco control

Indexed keywords

CANCER CONTROL; COMPLEX MODEL; JOURNAL ARTICLES; LUNG CANCER; LUNG MODEL; MODEL ASSUMPTIONS; MODELING NETWORKS; MODELING TECHNIQUE; NATIONAL CANCER INSTITUTE; NATURAL HISTORY; POPULATION TRENDS; TOBACCO CONTROL;

BIOLOGICAL ORGANS; MODEL STRUCTURES; MODELS; TOBACCO;

DISEASES;

CANCER; COMPARATIVE STUDY; DEMOGRAPHIC TREND; DISEASE INCIDENCE; MORTALITY; SPATIOTEMPORAL ANALYSIS; TOBACCO;

ALGORITHM; ARTICLE; CALIBRATION; COHORT ANALYSIS; HUMAN; INCIDENCE; LUNG TUMOR; NATIONAL HEALTH ORGANIZATION; PROBABILITY; PUBLIC HEALTH; SMOKING; SMOKING CESSATION; STATISTICAL MODEL; THEORETICAL MODEL; UNITED STATES;

ALGORITHMS; CALIBRATION; COHORT STUDIES; HUMANS; INCIDENCE; LUNG NEOPLASMS; MODELS, STATISTICAL; MODELS, THEORETICAL; NATIONAL CANCER INSTITUTE (U.S.); PROBABILITY; PUBLIC HEALTH; SMOKING; SMOKING CESSATION; UNITED STATES;

UNITED STATES;

NICOTIANA TABACUM;

EID: 84864911505     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/j.1539-6924.2011.01714.x     Document Type: Article

References (63)

1. Hazelton WD, Jeon J, Meza R, Moolgavkar SH. The FHCRC lung cancer model. Risk Analysis, 2012; 32(S1):S99-S116.
2. Schultz FW, Boer R, de Koning HJ. Description of MISCAN-Lung, the Erasmus MC lung cancer microsimulation model for evaluating cancer control interventions. Risk Analysis, 2012; 32(S1):S85-S98.
3. McMahon, PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Tramontano AC, Cipriano LE, Bouzan C, Gazelle GS. The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Analysis, 2012; 32(S1):S117-S124.
4. Levy DT, Blackman K, Zaloshnja E. A macro-model of smoking and lung cancer: Examining aggregate trends in lung cancer rates using the CPS-I and CPS-II and two-stage clonal expansion model. Risk Analysis, 2012; 32(S1):S125-S141.
5. Foy M, Deng L, Spitz M, Gorlova O, Kimmel M. Rice-MD Anderson lung cancer model. Risk Analysis, 2012; 32(S1):S142-S150.
6. Holford TR, Ebisu K, McKay L, Oh C, Zheng T. Yale lung cancer model. Risk Analysis, 2012; 32(S1):S151-S165.
7. Boer, Moolgavkar SH, Levy DT. Impact of tobacco control on lung cancer mortality in the United States over the period 1975-2000-Summary and limitations. Risk Analysis, 2012; 32(S1):S190-S202.
8. Anderson CM, Burns DM, Dodd KW, Feuer EJ. Birth-cohort specific estimates of smoking behaviors for the U.S. population. Risk Analysis, 2012; 32(S1):S14-S24.
9. Rosenberg MA, Feuer EJ, Yu B, Sun J, Henley SJ, Shanks TG, Anderson CM, McMahon PM, Thun MJ, Burns DM. Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Analysis, 2012; 32(S1):S25-S38.
10. Holford TR, Clarke LD. Development of the Counterfactual smoking histories. Risk Analysis, 2012; 32(S1):S39-S50.
11. Feuer EJ, Levy DT, McCarthy WJ. The impact of the reduction in tobacco smoking on U.S. lung cancer mortality, 1975-2000: An introduction to the problem. Risk Analysis, 2012; 32(S1):S6-S13.
12. Prorok P, Kramer B, Gohagan J. Screening theory and study design: The basics. In Kramer B, Gohagan J, Prorok P (eds). Cancer Screening, Theory and Practice. New York: Marcel Dekker, Inc., 1999.
13. Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. Journal of Clinical Oncology, 2007; 25(2):203-208.
14. Moolgavkar S, Venzon DJ. Two-event models for carcinogenesis: Incidence curves for childhood and adult tumors. Mathematical Biosciences, 1979; 47:55-77.
15. Moolgavkar SH, Knudson AG, Jr. Mutation and cancer: A model for human carcinogenesis. Journal of the National Cancer Institute, 1981; 66(6):1037-1052.
16. Little MP. Are two mutations sufficient to cause cancer? Some generalizations of the two-mutation model of carcinogenesis of Moolgavkar, Venzon, and Knudson, and of the multistage model of Armitage and Doll. Biometrics, 1995; 51(4):1278-1291.
17. Little MP, Muirhead CR, Stiller CA. Modelling lymphocytic leukaemia incidence in England and Wales using generalizations of the two-mutation model of carcinogenesis of Moolgavkar, Venzon and Knudson. Statistics in Medicine, 1996; 15(10):1003-1022.
18. Kai M, Luebeck EG, Moolgavkar SH. Analysis of the incidence of solid cancer among atomic bomb survivors using a two-stage model of carcinogenesis. Radiation Research, 1997; 148(4):348-358.
19. Luebeck EG, Heidenreich WF, Hazelton WD, Paretzke HG, Moolgavkar SH. Biologically based analysis of the data for the Colorado uranium miners cohort: Age, dose and dose-rate effects. Radiation Research, 1999; 152(4):339-351.
20. Moolgavkar S, Luebeck E, Krewski D, Zielinski J. Radon, cigarette smoke, and lung cancer: A re-analysis of the Colorado Plateau uranium miners' data. Epidemiology, 1993; 4(3):204-217.
21. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2002; 99(23):15095-15100.
22. Hazelton WD, Luebeck EG, Heidenreich WF, Moolgavkar SH. Analysis of a historical cohort of Chinese tin miners with arsenic, radon, cigarette smoke, and pipe smoke exposures using the biologically based two-stage clonal expansion model. Radiation Research, 2001; 156(1):78-94.
23. Hazelton WD, Clements MS, Moolgavkar SH. Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiology, Biomarkers & Prevention, 2005; 14(5):1171-1181.
24. Jeon J, Luebeck E, Moolgavkar S. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes and Control, 2006; 17(7):971-981.
25. Meza R, Hazelton WD, Colditz GA, Moolgavkar SH. Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model. Cancer Causes and Control, 2008; 19(3):317-328.
26. Grasl-Kraupp B, Luebeck G, Wagner A, Low-Baselli A, de Gunst M, Waldhor T, et al. Quantitative analysis of tumor initiation in rat liver: Role of cell replication and cell death (apoptosis). Carcinogenesis, 2000; 21(7):1411-1421.
27. Luebeck EG, Curtis SB, Cross FT, Moolgavkar SH. Two-stage model of radon-induced malignant lung tumors in rats: Effects of cell killing. Radiation Research, 1996; 145(2):163-173.
28. Luebeck EG, Curtis SB, Hazelton WD, Moolgavkar SH. The importance of promotion in lung carcinogenesis for protracted exposures to radon and radon progeny. Radiation Research, 2000; 154(6):730;discussion 30-1.
29. Moolgavkar SH, Luebeck EG, Turim J, Hanna L. Quantitative assessment of the risk of lung cancer associated with occupational exposure to refractory ceramic fibers. Risk Analysis, 1999; 19(4):599-611.
30. Moolgavkar SH, Luebeck EG, Anderson EL. Estimation of unit risk for coke oven emissions. Risk Analysis, 1998; 18(6):813-825.
31. Heidenreich WF, Luebeck EG, Moolgavkar SH. Some properties of the hazard function of the two-mutation clonal expansion model. Risk Analysis, 1997; 17(3):391-399.
32. Moolgavkar SH, Dewanji A, Venzon DJ. A stochastic two-stage model for cancer risk assessment. I. The hazard function and the probability of tumor. Risk Analysis, 1988; 8(3):383-392.
33. Moolgavkar SH, Luebeck G. Two-event model for carcinogenesis: Biological, mathematical, and statistical considerations. Risk Analysis, 1990; 10(2):323-341.
34. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: The Mayo program. Journal of Occupational Medicine, 1986; 28:746-750.
35. Marcus PM, Bergstralh EJ, Fagerstrom RM, Williams DE, Fontana R, Taylor WF, et al. Lung cancer mortality in the Mayo Lung Project: Impact of extended follow-up [see comment]. Journal of the National Cancer Institute, 2000; 92(16):1308-1316.
36. Etzel CJ, Amos CI, Spitz MR. Risk for smoking-related cancer among relatives of lung cancer patients. Cancer Research, 2003; 63(23):8531-8535.
37. Shen H, Spitz MR, Qiao Y, Guo Z, Wang LE, Bosken CH, et al. Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. International Journal of Cancer, 2003; 107(1):84-88.
38. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. Journal of National Cancer Institute, 2000; 92(21):1764-1772.
39. Kong CY, McMahon PM, Gazelle GS. Calibration of disease simulation models using an engineering approach. Value in Health, 2009; 12(4):521-529.
40. Miller DP, Liu G, De Vivo I, Lynch TJ, Wain JC, Su L, et al. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Research, 2002; 62:2819-2823.
41. Dai S, Mao C, Jiang L, Wang G, Cheng H. P53 polymorphism and lung cancer susceptibility: A pooled analysis of 32 case-control studies. Human Genetics.
42. McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, et al. Adopting helical CT screening for lung cancer: Potential health consequences during a 15-year period. Cancer, 2008; 113(12):3440-3449.
43. McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology, 2008; 248(1):278-287.
44. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute, 2000; 92:205-216.
45. Thun MJ, Myers DG, Day-Lally C, Namboodiri MM, Calle EE, Flanders D, et al. Age and the exposure-response relationships between cigarette smoking and premature death in Cancer Prevention Study II. Ch. 5 in NIH Publication 97-4213. Washington, DC, 1997.
46. U.S. Dept. of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Office of the Surgeon General, 2004.
47. Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Statistics in Medicine, 1987; 6(4):449-467.
48. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Statistics in Medicine, 1987; 6(4):469-481.
49. Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics, 1983; 39(2):311-324.
50. Holford TR, Zheng T, Mayne ST, McKay LA. Time trends of non-Hodgkin's lymphoma: Are they real? What do they mean? Cancer Research, 1992; 52(19 Suppl):5443s-5446s.
51. Meza R, Jeon J, Moolgavkar SH, Luebeck EG. Age-specific incidence of cancer: Phases, transitions, and biological implications. Proceedings of the National Academy of Sciences, 2008; 105(42):16284-16289.
52. Moolgavkar S, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973-2005. Cancer Causes and Control, 2009; 20(6):935-944.
53. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. British Medical Journal, 1994; 309(6959):901-911.
54. Flanders WD, Lally CA, Zhu B-P, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: Results from Cancer Prevention Study II. Cancer Research, 2003; 63(19):6556-6562.
55. Knoke JD, Shanks TG, Vaughn JW, Thun MJ, Burns DM. Lung cancer mortality is related to age in addition to duration and intensity of cigarette smoking: An analysis of CPS-I data. Cancer Epidemiology, Biomarkers & Prevention, 2004; 13(6):949-957.
56. Knoke JD, Burns DM, Thun MJ. The change in excess risk of lung cancer attributable to smoking following smoking cessation: An examination of different analytic approaches using CPS-I data. Cancer Causes and Control, 2008; 19(2):207-219.
57. Yun YH, Lim MK, Jung KW, Bae J-M, Park SM, Shin SA, et al. Relative and absolute risks of cigarette smoking on major histologic types of lung cancer in Korean men. Cancer Epidemiology, Biomarkers & Prevention, 2005; 14(9):2125-2130.
58. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking cessation in relation to mortality in women. Journal of the American Medical Association, 2008; 299(17):2037-2047.
59. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nature Medicine, 2008; 14(8):812-813.
60. Broet P, Camilleri-Broet S, Zhang S, Alifano M, Bangarusamy D, Battistella M, et al. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: Implications for chemotherapy selection. Cancer Research, 2009; 69(3):1055-1062.
61. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clinical Cancer Research, 2008; 14(17):5565-5570.
62. Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. Journal of Clinical Oncology, 2008; 26(6):877-883.
63. Centers for Disease Control and Prevention. Cigarette smoking among adults and trends in smoking cessation-United States, 2008. Morbidity and Mortality Weekly Report, 2009; 58(44):1227-1232.